Warang P, Singh G, Moshir M, Binazon O, Laghlali G, Chang L
Hum Vaccin Immunother. 2025; 21(1):2470542.
PMID: 40028815
PMC: 11881870.
DOI: 10.1080/21645515.2025.2470542.
Li L, He Y, Zhao J, Yin H, Feng X, Fan X
Clin Rev Allergy Immunol. 2025; 68(1):21.
PMID: 39982546
DOI: 10.1007/s12016-025-09030-9.
Li S, Zhou C, Li W, Kang L, Mu H
Medicine (Baltimore). 2025; 103(52):e40893.
PMID: 39969330
PMC: 11688059.
DOI: 10.1097/MD.0000000000040893.
Rana A, Mishra A, Awasthi S
RSC Adv. 2025; 15(6):4496-4525.
PMID: 39931410
PMC: 11808662.
DOI: 10.1039/d4ra07989b.
Franco-Fuquen P, Figueroa-Aguirre J, Martinez D, Moreno-Cortes E, Garcia-Robledo J, Vargas-Cely F
J Transl Autoimmun. 2025; 10:100264.
PMID: 39931050
PMC: 11808717.
DOI: 10.1016/j.jtauto.2024.100264.
Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus.
Hurez V, Gauderat G, Soret P, Myers R, Dasika K, Sheehan R
iScience. 2025; 28(2):111754.
PMID: 39925417
PMC: 11804754.
DOI: 10.1016/j.isci.2025.111754.
Deep learning-based prediction of autoimmune diseases.
Yang D, Peng X, Zheng S, Peng S
Sci Rep. 2025; 15(1):4576.
PMID: 39920178
PMC: 11806040.
DOI: 10.1038/s41598-025-88477-4.
Assessing the therapeutic potential of vagus nerve stimulation in autoimmune diseases: A systematic review.
Chan E, Mani A
Physiol Rep. 2025; 13(3):e70230.
PMID: 39903575
PMC: 11793006.
DOI: 10.14814/phy2.70230.
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.
Huang Q, Zhu X, Zhang Y
Biomark Res. 2025; 13(1):23.
PMID: 39901288
PMC: 11792665.
DOI: 10.1186/s40364-025-00736-8.
Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy.
Le J, Sun Y, Deng G, Dian Y, Xie Y, Zeng F
Hum Vaccin Immunother. 2025; 21(1):2458948.
PMID: 39894761
PMC: 11792813.
DOI: 10.1080/21645515.2025.2458948.
Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.
Parvin N, Joo S, Mandal T
J Funct Biomater. 2025; 16(1).
PMID: 39852580
PMC: 11766201.
DOI: 10.3390/jfb16010024.
The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.
Swierczek A, Batko D, Wyska E
Pharmaceutics. 2025; 16(12.
PMID: 39771538
PMC: 11676367.
DOI: 10.3390/pharmaceutics16121559.
Recent advances in the role of mesenchymal stem cells as modulators in autoinflammatory diseases.
Chen B, Chen Z, He M, Zhang L, Yang L, Wei L
Front Immunol. 2025; 15:1525380.
PMID: 39759531
PMC: 11695405.
DOI: 10.3389/fimmu.2024.1525380.
CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?.
Rangel-Pelaez C, Martinez-Gutierrez L, Tristan-Manzano M, Callejas J, Ortego-Centeno N, Martin F
Front Immunol. 2025; 15:1502712.
PMID: 39742256
PMC: 11685126.
DOI: 10.3389/fimmu.2024.1502712.
Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics.
Li X, Wei Y, Zhang Z, Zhang X
Extracell Vesicles Circ Nucl Acids. 2024; 5(1):44-63.
PMID: 39698409
PMC: 11648408.
DOI: 10.20517/evcna.2023.58.
Breaking barriers: advancing cellular therapies in autoimmune disease management.
Fu Y, Feng C, Qin S, Xing Z, Liu C, Liu Z
Front Immunol. 2024; 15:1503099.
PMID: 39676874
PMC: 11638217.
DOI: 10.3389/fimmu.2024.1503099.
Advances in the study of artemisinin and its derivatives for the treatment of rheumatic skeletal disorders, autoimmune inflammatory diseases, and autoimmune disorders: a comprehensive review.
Long Z, Xiang W, Xiao W, Min Y, Qu F, Zhang B
Front Immunol. 2024; 15:1432625.
PMID: 39524446
PMC: 11543433.
DOI: 10.3389/fimmu.2024.1432625.
Antigen-specific modulation of chronic experimental autoimmune encephalomyelitis in humanized mice by TCR-like antibody targeting autoreactive T-cell epitope.
Goor A, Altman E, Arman I, Erez S, Haus-Cohen M, Reiter Y
Life Sci Alliance. 2024; 8(1).
PMID: 39496501
PMC: 11536346.
DOI: 10.26508/lsa.202402996.
Advances in hematopoietic stem cell transplantation for autoimmune diseases.
Xu Y, Wang X, Hu Z, Huang R, Yang G, Wang R
Heliyon. 2024; 10(20):e39302.
PMID: 39492896
PMC: 11530805.
DOI: 10.1016/j.heliyon.2024.e39302.
Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.
Klekotka P, Lavoie L, Mitchell B, Iheanacho I, Burge R, Cohee A
Front Immunol. 2024; 15:1425478.
PMID: 39483464
PMC: 11524942.
DOI: 10.3389/fimmu.2024.1425478.